Syndax Pharmaceuticals Inc Stockholders Equity

• Syndax Pharmaceuticals Inc showed a decrease of -77.6% in Stockholders Equity from 2024 to 2025.
• This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: $113.85 million | Q2 2016: $106.24 million | Q3 2016: $93.83 million | Q1 2017: $72.62 million | Q2 2017: $109.34 million | Q3 2017: $96.71 million | Q1 2018: $86.95 million | Q2 2018: $70.35 million | Q3 2018: $64.27 million | Q1 2019: $68.63 million | Q2 2019: $55.28 million | Q3 2019: $44.04 million | Q1 2020: $53.51 million | Q2 2020: $147.65 million | Q3 2020: $131.98 million | Q1 2021: $228.21 million | Q2 2021: $214.56 million | Q3 2021: $199.00 million | Q1 2022: $374.55 million | Q2 2022: $361.94 million | Q3 2022: $338.10 million | Q1 2023: $435.51 million | Q2 2023: $400.04 million | Q3 2023: $359.19 million | Q1 2024: $491.89 million | Q2 2024: $434.34 million | Q3 2024: $366.43 million | Q1 2025: $215.06 million | Q2 2025: $157.42 million | Q3 2025: $115.43 million.
• Over the full 13 years of available data (2013 to 2025), Syndax Pharmaceuticals Inc's Stockholders Equity has grown by 150.3%.
• Historical annual values: Fiscal year 2025: $64.63 million | Fiscal year 2024: $288.12 million | Fiscal year 2023: $554.20 million | Fiscal year 2022: $467.45 million | Fiscal year 2021: $408.37 million | Fiscal year 2020: $252.19 million | Fiscal year 2019: $31.60 million | Fiscal year 2018: $53.05 million | Fiscal year 2017: $104.32 million | Fiscal year 2016: $84.14 million | Fiscal year 2015: -$252.42 million | Fiscal year 2014: -$152.57 million | Fiscal year 2013: -$128.48 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026